What is the primary reason for this amended 10-Q filing?

This filing is an amendment to correct and restate the Company's financial statements for the period ended June 30, 2003, and prior periods. The restatements were necessary to correct certain historical accounting policies to conform to U.S. generally accepted accounting principles (GAAP) and to correct certain errors made in the application of GAAP, including issues related to tax contingency reserves and revenue recognition for wholesaler sales.

How did the restatements impact the company's financial position?

The restatements resulted in adjustments to retained earnings and various financial statement line items. Notably, cash and cash equivalents decreased by approximately $2.0 billion as certain investments were reclassified to marketable securities. Net earnings for the six months ended June 30, 2003, were positively impacted by approximately $55 million, or $0.03 per share, due to the restatement adjustments.

What are the key drivers of the company's sales growth in the reported period?

Sales growth was driven by a combination of factors including increased sales volume, favorable foreign exchange rates, and price increases. The Pharmaceuticals segment, in particular, saw strong performance from key products such as Pravachol, Plavix, and Abilify. The company also benefited from the workdown of wholesaler inventories, which impacted comparability with the prior year.

What are the significant legal and contingent liabilities the company is facing?

Bristol-Myers Squibb is involved in numerous legal proceedings and investigations, including those related to pricing, sales and marketing practices, product liability (such as for PPA, Serzone, and Stadol NS), intellectual property disputes (e.g., PLAVIX patent litigation), and accounting issues. The company has established reserves for some of these matters, but the ultimate outcomes and potential financial impact remain uncertain and could be material.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2003

Summary

Bristol-Myers Squibb Company (BMY) filed an Amendment No. 1 to its Form 10-Q for the quarterly period ended June 30, 2003. This filing primarily presents restated consolidated financial statements due to corrections in accounting policies and errors in the application of GAAP. The restatements impacted periods prior to 2001 and the first three quarters of 2003. Key areas of adjustment included tax contingency reserves, revenue recognition for wholesaler sales, and the classification of cash and cash equivalents. Despite the restatements, the company reported solid sales growth for the second quarter and first six months of 2003, driven by strong performance in its Pharmaceuticals segment, particularly from key brands like Pravachol, Plavix, and Abilify. The company also highlighted progress in its strategic alliances and product development. However, significant ongoing legal proceedings and investigations related to pricing, sales practices, and product liability continue to pose substantial risks that could materially impact future financial performance.

Key Highlights

1Restated financial statements for periods prior to 2001 and for the first three quarters of 2003 to correct accounting policies and application errors, impacting retained earnings and financial statement line items.
2Reported a 25% increase in worldwide sales for Q2 2003 to $5.13 billion and a 12% increase for the first six months to $9.86 billion, driven by volume, price, and favorable foreign exchange.
3Pharmaceuticals segment showed robust growth, with Q2 sales up 30% to $3.63 billion, led by strong performances from Pravachol, Plavix, and Abilify.
4Significant ongoing legal proceedings and investigations concerning pricing, sales and marketing practices, and product liability are noted, with substantial reserves being established for certain matters.
5Cash and cash equivalents were reduced by approximately $2.0 billion due to reclassification as marketable securities, while marketable securities increased by the same amount.
6The company is addressing 'material weaknesses' identified in its financial reporting controls, with remediation efforts ongoing, particularly concerning income tax accounting.
7Introduced new product 'Abilify' in the US in November 2002, achieving over a 5% weekly new prescription share in the US antipsychotic market by Q2 2003.

BRISTOL MYERS SQUIBB CO Quarterly Report (Amendment) for Q2 Ended Jun 30, 2003

Summary

Key Highlights

Frequently Asked Questions